Peptides
Evidence: moderate_human
Hexarelin (Examorelin) is a synthetic hexapeptide GHS-R1a agonist and the most potent synthetic GH secretagogue by peak GH release. It stimulates GH release through both pituitary ghrelin receptors and hypothalamic pathways, with mechanisms involving regulation of GHRH and somatostatin. Hexarelin also demonstrates significant cardiac benefits through activation of cardiac GHS-R1a receptors, protecting against ischemia-reperfusion injury and reducing cardiac fibrosis via the CD36 scavenger receptor pathway.
Standard: Research indicates 100-200 mcg administered 1-2 times daily via subcutaneous injection.
Maintenance: Research indicates 100 mcg at bedtime. Note: desensitization occurs rapidly.
Administration: subcutaneousintramuscularintranasal
Timing: On empty stomach, bedtime preferred. Avoid prolonged continuous use due to rapid desensitization.
Duration: 4-8 week cycles maximum, then 4+ week break. Hexarelin desensitizes faster than other GHRPs.
Hexarelin produces the highest peak GH release of any synthetic secretagogue but desensitizes rapidly (within 2-4 weeks of continuous use), making it unsuitable for long-term protocols. Its unique cardiac protective properties (via CD36 receptors) make it of particular interest for cardiac optimization. Best used in short bursts rather than sustained protocols. The desensitization issue limits its practical utility compared to Ipamorelin.
Research-grade supplier. Less commonly available through compounding pharmacies than Ipamorelin/GHRP-2.
Take the free assessment and get personalized recommendations based on your biology and goals.
Get Your Free Protocolor take the assessment →